Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and pha 848125

quinazolines has been researched along with pha 848125 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amboldi, N; Ballinari, D; Brasca, MG; Cameron, A; Casale, E; Cervi, G; Ciomei, M; Colombo, M; Colotta, F; Croci, V; D'Alessio, R; Fiorentini, F; Isacchi, A; Mercurio, C; Moretti, W; Panzeri, A; Pastori, W; Pevarello, P; Quartieri, F; Roletto, F; Traquandi, G; Vianello, P; Vulpetti, A1
Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G1
Alzani, R; Ciomei, M; Degrassi, A; Fanti, S; Giusti, AM; Nanni, C; Patton, V; Pesenti, E; Russo, M; Texido, G1
Albanese, C; Alzani, R; Amboldi, N; Avanzi, N; Ballinari, D; Brasca, MG; Ciomei, M; Colotta, F; Festuccia, C; Fiorentini, F; Galvani, A; Isacchi, A; Locatelli, G; Mercurio, C; Moll, J; Pastori, W; Patton, V; Pesenti, E; Roletto, F1
Blaydorn, L; Borad, MJ; Ciomei, M; Fiorentini, F; Hidalgo, M; Isaacs, JD; Jameson, G; Jimeno, A; Laheru, D; Pacciarini, MA; Ramanathan, RK; Scaburri, A; Tibes, R; Von Hoff, DD; Weiss, GJ1
Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Ciomei, M; D'Atri, S; Del Bufalo, D; Desideri, M; Esposito, AI; Levati, L; Pfeffer, U1
Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E1
Bolin, S; Borgenvik, A; Bradner, JE; Cho, YJ; Persson, CU; Qi, J; Sundström, A; Swartling, FJ; Weishaupt, H; Weiss, WA1
Chen, BY; Clark, PM; Damoiseaux, R; Ghezzi, C; Ribalet, B; Wong, A1

Trials

1 trial(s) available for quinazolines and pha 848125

ArticleYear
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adolescent; Adult; Aged; Cyclin-Dependent Kinases; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, trkA; Treatment Outcome; Young Adult

2012

Other Studies

8 other study(ies) available for quinazolines and pha 848125

ArticleYear
Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Journal of medicinal chemistry, 2009, Aug-27, Volume: 52, Issue:16

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Pyrazoles; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous

2009
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
    Pharmacological research, 2010, Volume: 61, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles

2010
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Cyclin-Dependent Kinases; Diagnostic Imaging; Disease Models, Animal; Drug Evaluation, Preclinical; Genes, ras; Glycine; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Pyrazoles; Quinazolines; Treatment Outcome

2010
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:8

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Humans; Mice; Multigene Family; Phosphorylation; Protein Kinases; Pyrazoles; Quinazolines; Rats; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
    Biochemical pharmacology, 2012, Sep-01, Volume: 84, Issue:5

    Topics: Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinases; Down-Regulation; Gene Regulatory Networks; Humans; Melanoma; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogenes; Pyrazoles; Quinazolines; RNA, Small Interfering; Securin

2012
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
    British journal of pharmacology, 2013, Volume: 169, Issue:1

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays

2013
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Oncogene, 2018, Volume: 37, Issue:21

    Topics: Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Cyclin-Dependent Kinase 2; Drug Synergism; Female; Humans; Medulloblastoma; Piperazines; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays

2018
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
    Nature communications, 2019, 11-29, Volume: 10, Issue:1

    Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glucose; Glucose Transporter Type 1; High-Throughput Screening Assays; Humans; Lung Neoplasms; Phenylenediamines; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; RNA Polymerase II; RNA, Messenger; Signal Transduction; Triazines

2019